Biodesix announces new data presentation at chest 2024 annual meeting and the launch of a complementary clinical study

Louisville, colo.--(business wire)--biodesix, inc. (nasdaq: bdsx), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the chest annual meeting 2024 in boston, massachusetts on tuesday, october 8 at 10:20 am et. the presentation will detail the experience of healthcare providers using the nodify lung® nodule risk assessment in over 35,000 patients consecutively tested in a real-world clinical setting. guidelines recommend that.
BDSX Ratings Summary
BDSX Quant Ranking